3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
2
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Head & Neck
1
Dermatologic
1
Conditions
Squamous Cell Carcinoma of Head and Neck
1
Melanoma
1
Interventions
pembrolizumab
62
Nivolumab
40
Ipilimumab
24
trametinib
13
dabrafenib
10
Specimen Handling
10
Magnetic Resonance Spectroscopy
10
binimetinib
9
Cyclophosphamide
8
CTLA-4 Antigen
8
Biopsy
8
encorafenib
7
fludarabine
6
Radiosurgery
6
Cisplatin
6
relatlimab
5
cemiplimab
5
atezolizumab
5
Pemetrexed
5
Introns
5
Interleukin-2
5
tislelizumab
4
lenvatinib
4
fludarabine phosphate
4
durvalumab
4
dostarlimab
4
cobimetinib
4
avelumab
4
Radiotherapy
4
Paclitaxel
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Active not recruiting
×
Melanoma
×
Tumor Necrosis Factor-alpha
×
Clear all
NCT05222932
2025-08-07
AVENTIL
TILT Biotherapeutics Ltd.
Phase 1
Active not recruiting
15 enrolled